Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Aclaris Therapeutics, Inc.”

18 pharma patents match "Aclaris Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 18
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 18 pharmaceutical patents matching "Aclaris Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

18 results for “Aclaris Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12403141

    Deuterated MK2 pathway inhibitors and methods of using the same

    Aclaris Therapeutics, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted

  2. US 12370195

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Aclaris Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted

  3. US 12297203

    Pyrrolopyrimidine ITK inhibitors

    Aclaris Therapeutics, Inc. · Granted May 13, 2025 · Expires May 8, 2045

    granted

  4. US 12281111

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Aclaris Therapeutics, Inc. · Granted Apr 22, 2025 · Expires Apr 17, 2045

    granted

  5. US 11844801

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Aclaris Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted

  6. US 11820775

    Pyrrolopyrimidine ITK inhibitors

    Aclaris Therapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted

  7. US 11739086

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Aclaris Therapeutics, Inc. · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted

  8. US 10981906

    Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

    Aclaris Therapeutics, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  9. US 10800775

    Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same

    Aclaris Therapeutics, Inc. · Granted Oct 13, 2020 · Expires Oct 8, 2040

    granted

  10. US 10729720

    Peroxide formulations and methods and applicators for using the same

    Aclaris Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted

  11. US 10653721

    Peroxide formulations and methods and applicators for using the same

    Aclaris Therapeutics, Inc. · Granted May 19, 2020 · Expires May 14, 2040

    granted

  12. US 10493103

    Peroxide formulations and methods and applicators for using the same

    Aclaris Therapeutics, Inc. · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted

  13. US 10335391

    Stabilized oxymetazoline formulations and their uses

    Aclaris Therapeutics, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  14. US 10316038

    Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer

    Aclaris Therapeutics, Inc. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  15. US 10150783

    Heterocyclic ITK inhibitors for treating inflammation and cancer

    Aclaris Therapeutics, Inc. · Granted Dec 11, 2018 · Expires Dec 6, 2038

    granted

  16. US 10098910

    Peroxide formulations and methods and applicators for using the same

    Aclaris Therapeutics, Inc. · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted

  17. US 9980983

    Peroxide formulations and methods and applicators for using the same

    Aclaris Therapeutics, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted

  18. US 9675639

    Peroxide formulations and methods and applicators for using the same

    Aclaris Therapeutics, Inc. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.